Omega Therapeutics IPO Presentation Deck
Omega's platform has the potential to be an unprecedented and pioneering
approach to high-value transformative therapies in pursuit of high-value targets
Focus "table-stakes" of most gene-
based therapies
Select Monogenic Diseases
Precisely correct genetic or epigenetic dysregulation in
monogenic rare and non-rare diseases
(e.g., alopecia, Hypercholesterolemia, Fragile X, FA)
©2021 Omega Therapeutics, Inc.
Omega's transformative value creation
Regenerative Medicine
Recapitulate developmental and mature-state gene
expression to drive cellular regeneration and restore normal
function (e.g., Liver, Pancreas, Heart, Cornea regen., T cell prog.)
Multigenic Diseases
Including Immunology
Precisely up- or down-regulate single or multiple genes within an
IGD
or across IGDs (e.g., ARDS (Covid19), RA, IBD, Obesity, CHF, IPF)
Oncology
Precisely regulate target oncogenes
including historically challenging or un-druggable targets in
various cancers (e.g., HCC, NSCLC, Pancreatic cancer.
GBM)
Source: Evaluate pharma, market research reports, internal analysis
Market
potential
$25B+
$ 150B+
$100B+
14View entire presentation